Cardiovascular Drugs Global Market Report 2018

1. Cardiovascular Drugs Global Market Report 2018 Including: Anti-hypertensive Drugs; Other Drugs For Cardiovascular Diseases; Hypolipidemics; Anti Thrombotics Covering: Merck & Co., Sanofi S.A, Pfizer Inc., Bristol-Myers Squibb Company, Novartis AG Feb 2018

2. Reasons to Purchase • Outperform competitors using accurate up to date demand-side dynamics information. • Identify growth segments for investment. • Facilitate decision making on the basis of historic and forecast data and the drivers and restraints on the market. • Create regional and country strategies on the basis of local data and analysis. • Stay abreast of the latest customer and market research findings • Benchmark performance against key competitors. • Develop strategies based on likely future developments. • Utilize the relationships between key data sets for superior strategizing. • Suitable for supporting your internal and external presentations with reliable high quality data and analysis • Gain a global perspective on the development of the market. • Report will be updated with the latest data and delivered to you within 3-5 working days of order. Scope Markets Covered: Anti-hypertensive Drugs; Other Drugs For Cardiovascular Diseases; Hypolipidemics; Anti Thrombotics. Companies Mentioned:Merck & Co., Sanofi S.A, Pfizer Inc., Bristol-Myers Squibb Company, Novartis AG Countries: Brazil, China, France, Germany, India, Italy, Japan, Spain, Russia, UK, USA and Australia. Regions: Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East And Africa Time series: Five years historic and forecast. Data: Ratios of market size and growth to related markets, GDP, Expenditure Per Capita, Cardiovascular Drugs Indicators Comparison. Data segmentations: Country and regional historic and forecast data, market share of competitors, market segments. Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.

3. Cardiovascular Drugs Cardiovascular Drugs Market Characteristics Characteristics Market Cardiovascular drugs market covers the drugs used to treat conditions that affect the heart or blood vessels. These conditions include heart stroke, coronary artery diseases, valvular diseases, peripheral venous diseases, pericarditis, endocarditis, cardiac tumors, arteriosclerosis, and lymphatic diseases. Some of the major cardiovascular drugs include anti-hypertensive drugs such as calcium channel blockers and Angiotensin II receptor antagonists, and hypolipidemic drugs such as fibric acid derivatives and bile acid binding resins. The market numbers within this briefing are restricted to pharmaceutical (drug) treatments and do not cover biologic treatments for these conditions which are included in a separate briefing. The cardiovascular drugs industry is further classified as follows– Anti-Hypertensive Drugs are used to Hypolipidemic Drugs are those drugs that lower lipid and Antithrombotics Drugs are used to prevent and Other (Congestive Heart Failure, Antiarrhythmic and Antianginal) Drugs are the drugs that prevent congestive heart failure, drugs used for In this report market value is defined as the revenues organizations earn by selling their goods and services within the specified market, based on the price at which they sell. Only goods and services traded between entities are included.

4. The revenues for a specified geography are consumption values – that is, they are revenues generated by organizations in the specified geography within the specified market, irrespective of where they are produced.

5. Cardiovascular Drugs Cardiovascular Drugs Market Historic Growth Historic Growth Market The global cardiovascular drugs market grew from $X billion in 2013 to $X billion in 2017 at a compound annual growth rate (CAGR) of X%. The chart and table below shows the year-on-year growth of the global cardiovascular drugs market during 2013 – 2017. Drivers of the Market: Restraints on the Market:

6. Cardiovascular Drugs Cardiovascular Drugs Market Forecast Growth Forecast Growth Market The global cardiovascular drugs market is expected to grow from $XX billion in 2017 to $141.4 billion in 2021 at a compound annual growth rate (CAGR) of XX%. The forecasted growth in this market can be attributed to the increase in aging population, increase in the prevalence of cardiovascular diseases and availability of more generic drugs that reduce the cost of treatment. The chart and table below shows the year-on-year growth of the global cardiovascular drugs market during 2017 - 2021. Drivers of the Market: Restraints on the Market:

7. Cardiovascular Drugs Cardiovascular Drugs Market Segmentation Segmentation Market The chart and table below shows the split of the cardiovascular drugs market in 2017. The total market value for cardiovascular drugs was $X billion in 2017. The markets that are covered include Anti-hypertensive Drugs; Other Drugs For Cardiovascular Diseases; Hypolipidemics; Anti Thrombotics. Anti-hypertensive Drugs was the X largest segment in the cardiovascular drugs market with X% share of the market. The market value for the anti-hypertensive drugs was $X billion in 2017. Other Drugs For Cardiovascular Diseases made up around X% share of the market. The market value for the other drugs for cardiovascular diseases was $X billion in 2017.

8. Cardiovascular Drugs Cardiovascular Drugs Market Regional Regional And Country Analysis And Country Analysis Market The Asia Pacific was the largest region in the cardiovascular drugs market in 2017, cardiovascular drugs for $X billion or X% market share. North America was the x largest region cardiovascular drugs for $X billion or X% market share. Western Europe was the x largest region cardiovascular drugs for $X billion or X% market share.

9. Ca Cardiovascular Drugs rdiovascular Drugs Market Competitive Landscape Competitive Landscape Market The leading competitors in the global cardiovascular drugs market are Merck & Co., Sanofi S.A, Pfizer Inc., Bristol-Myers Squibb Company, Novartis AG. The chart and table below displays the percentage market share of the top players in the cardiovascular drugs market industry. Merck & Co. generated revenues of $XX billion for the financial year 2016, an XX% increase from the previous year. Sanofi S.A. generated revenues of $XX billion for the financial year 2016, an XX% decrease from the previous year. Pfizer Inc. generated revenues of $XX billion for the financial year 2016, an XX% increase from the previous year.

10. Bristol-Myers Squibb Company generated revenues of $XX billion for the financial year 2016, an XX% increase from the previous year. Novartis AG generated revenues of $XX billion for the financial year 2016, an XX% decrease from the previous year. Eli Lilly And Company generated revenues of $XX billion for the financial year 2016, an XX% increase from the previous year. Johnson & Johnson generated revenues of $XX billion for the financial year 2016, an XX% decrease from the previous year. AstraZeneca Plc. generated revenues of $XX billion for the financial year 2016, an XX% decrease from the previous year. Abbott Laboratories Inc. generated revenues of $XX billion for the financial year 2016, an XX% increase from the previous year. Bayer AG generated revenues of $XX billion for the financial year 2016, an XX% increase from the previous year. Company Profile Merck & Co. Overview Merck & Co. was the largest company in the cardiovascular drugs market with a XX% share of the market in 2017. The company was founded in 1891 and is headquartered in New Jersey, USA. It offers therapeutic and

11. Products and Services Merck & Co. operates through following divisions – The Pharmaceutical division offers The Animal Health division is involved in The Healthcare Services division offers Strategy Merck & Co.’s growth strategy is to enhance its global cardiovascular business by expanding its research facilities. In January 2017, the company started the construction of its new research facility in South San Francisco which is expected to be ready by 2019. This facility is expected to have nine stories and 290,000 square feet of research and office space that will be used for research on Financial Performance Merck’s Primary Care and Women's Health section in Pharmaceutical division, involved in cardiovascular drugs manufacturing, generated revenues of $XX billion for the financial year 2016, a XX% decrease from the previous year. The company had a market Sanofi S.A Overview Products and Services Strategy Financial Performance preventive health solutions through prescription medicines, vaccines, biologic therapies and animal health products. Merck & Co. serves drug wholesalers and retailers, hospitals, government agencies and entities, physicians, physician distributors, veterinarians, distributors, animal producers, and managed health care providers.

12. Pfizer Inc. Overview Products and Services Strategy Financial Performance Bristol-Myers Squibb Company Overview Products and Services Strategy Financial Performance Novartis AG Overview Products and Services Strategy Financial Performance